GlassScriptPhysician profile
Robert Paul Margolis
NPI 1497732812
$3,531.92
in general payments reported to CMS, 2019-2025
15 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.57 · 2020: $341 · 2021: $447 · 2022: $770 · 2023: $933 · 2024: $719 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.29 |
| Education | $127.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,188.25 | 2021-2025 | |
| Allergan, INC. | $698.60 | 2020-2022 | |
| Biogen, INC. | $188.12 | 2022-2024 | Tecfidera, Tysabri, Tysabri |
| Pfizer INC. | $121.11 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $80.85 | 2019-2024 | |
| Lilly USA, LLC | $68.62 | 2022-2023 | Reyvow, Emgality |
| E.R. Squibb & Sons, L.L.C. | $44.23 | 2020 | |
| Emd Serono, INC. | $28.84 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.85 | 2022 | |
| Celgene Corporation | $18.59 | 2024 | Zeposia |
| Ucb, INC. | $16.87 | 2024 | Rystiggo |
| Supernus Pharmaceuticals, INC. | $14.81 | 2021 | |
| Mdd US Operations, LLC | $13.84 | 2020 | |
| Medtronic, INC. | $13.48 | 2022 | |
| Amgen INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.